




Behandeling met het afweersysteem?

Iris de Weerd
Arts-onderzoeker
Afdeling Hematologie
Lymmcare symposium 17-11-2017





Afweersysteem: 'killer' T cellen







Maar bij CLL...



Immuuntherapie: lenalidomide



- Multipel myeloom




- Multipel myeloom
- CLL
- Lymfomen


Immuuntherapie: BiTE

Bispecific T cell Engager

- Blinatumomab bij ALL



Immuuntherapie: CAR T cellen



T cel therapie nu



- Verschillende succesvolle vormen

Maar nog ruimte voor verbetering:


- Hoge kosten
- Veel bijwerkingen




T cel therapie nu



T cel therapie nu








Regulatoire T cel






Antistoffen






Antistof




Nanobody





Waarom nanobodies?

- Klein & stabiel
- Goedkoop
- Verschillende nanobodies koppelen













Effect nanobodies?



versus



Nanobodies in het lab



Dankwoord



Funding:
AMC MD/PhD Scholarship
Egberts Stichting
Peters van der Laanstichting

